@article{5140b37a8e124d4287a3d53464645c7f,
title = "Ubc9 deficiency selectively impairs the functionality of common lymphoid progenitors (CLPs) during bone marrow hematopoiesis",
abstract = "Hematopoietic development occurs in the bone marrow, and this process begins with hematopoietic stem cells (HSCs). Ubc9 is a unique E2-conjugating enzyme required for SUMOylation, an evolutionarily conserved post-translational modification system. We herein show that a conditional Ubc9 deletion in the hematopoietic system caused decreased thymus weight and reduced lymphocyte to myeloid cell ratio. Importantly, Ubc9 deletion in the hematopoietic system only selectively impaired the development of common lymphoid progenitors (CLPs) in the bone marrow and perturbed their potential to differentiate into lymphocytes, thereby decreasing the number of T/B cells in the periphery. Ubc9 was found to be required for CLP viability, and therefore, Ubc9 deficiency rendered CLPs to undergo apoptosis and attenuated their proliferation. Thus, Ubc9 plays a critical role in the regulation of CLP function during hematopoietic development in the bone marrow.",
keywords = "Common lymphoid progenitors, Hematopoietic development, Ubc9",
author = "Edrees, {Mohammed Abdelssalam Hassan} and Jiahui Luo and Fei Sun and Faxi Wang and Long He and Tiantian Yue and Longmin Chen and Jing Zhang and Haifeng Zhou and Chunliang Yang and Ping Yang and Fei Xiong and Qilin Yu and Adam, {Bao Ling} and Furong Liu and Jinxiu Li and Shu Zhang and Wang, {Cong Yi}",
note = "Funding Information: This study was supported by the National Natural Science Foundation of China (81530024, 9174920038, 81471046, 81770823 and 81670929), the Ministry of Science and Technology (2016YFC1305002 and 2017YFC1309603), NHC Drug Discovery Program (2017ZX09304022-07), the Department of Science and Technology of Hubei State (2017ACA096), the Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College, Huazhong University of Science and Technology, and the Innovative Funding for Translational Research from Tongji Hospital. Funding Information: This study was supported by the National Natural Science Foundation of China ( 81530024 , 9174920038 , 81471046 , 81770823 and 81670929 ), the Ministry of Science and Technology ( 2016YFC1305002 and 2017YFC1309603 ), NHC Drug Discovery Program ( 2017ZX09304022-07 ), the Department of Science and Technology of Hubei State ( 2017ACA096 ), the Integrated Innovative Team for Major Human Disease Programs of Tongji Medical College, Huazhong University of Science and Technology, and the Innovative Funding for Translational Research from Tongji Hospital. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",
year = "2019",
month = oct,
doi = "10.1016/j.molimm.2019.08.003",
language = "English (US)",
volume = "114",
pages = "314--322",
journal = "Immunochemistry",
issn = "0161-5890",
publisher = "Elsevier Limited",
}